Regulus Therapeutics Completes Enrollment Of Fourth Cohort In Phase 1b Multiple-Ascending Dose Clinical Trial Of RGLS8429 For Treatment Of Autosomal Dominant Polycystic Kidney Disease With 26 Patients Enrolled
Portfolio Pulse from Benzinga Newsdesk
Regulus Therapeutics has completed enrollment for the fourth cohort in its Phase 1b clinical trial of RGLS8429, aimed at treating Autosomal Dominant Polycystic Kidney Disease. A total of 26 patients have been enrolled in this multiple-ascending dose study.

October 08, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regulus Therapeutics has successfully enrolled 26 patients in the fourth cohort of its Phase 1b trial for RGLS8429, targeting Autosomal Dominant Polycystic Kidney Disease. This milestone could positively influence investor sentiment.
The completion of patient enrollment in a clinical trial is a significant milestone, indicating progress in the development of RGLS8429. This can lead to positive investor sentiment as it shows the company is advancing in its clinical pipeline.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90